GlassScriptPhysician profile
Elisabeth Batson
NPI 1629472832
$1,356.52
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,357.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $190.30 | 2021 | |
| Abbvie INC. | $179.57 | 2021 | |
| Ucb, INC. | $126.91 | 2021 | |
| Neurelis, INC. | $125.38 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $120.76 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.40 | 2021 | |
| Adlon Therapeutics L.P. | $81.27 | 2021 | |
| Supernus Pharmaceuticals, INC. | $75.22 | 2021 | |
| Eisai INC. | $72.75 | 2021 | |
| Neos Therapeutics, LP | $69.09 | 2021 | |
| Aquestive Therapeutics, INC. | $55.50 | 2021 | |
| Amgen INC. | $52.80 | 2021 | |
| Currax Pharmaceuticals LLC | $43.71 | 2021 | |
| Amneal Pharmaceuticals LLC | $42.20 | 2021 | |
| Saol Therapeutics INC. | $30.66 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elisabeth Batson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.